Stock BIOV BIOVAXYS TECHNOLOGY CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Company BioVaxys Technology Corp.

Equities

BIOV

CA09076M1014

Biotechnology & Medical Research

Delayed Canadian Securities Exchange
Other stock markets
 09:48:50 2024-04-25 am EDT 		5-day change 1st Jan Change
0.085 CAD +6.25% Intraday chart for BioVaxys Technology Corp. +6.25% +70.00%
Apr. 10 Biovaxys and SpayVac-For-Wildlife, Inc. Announce Launch of Field Trial for Large-Scale Immunocontraception in the Commercial Aquatic Farming Industry CI
Apr. 03 BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMage CI

Business Summary

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

Managers

Managers TitleAgeSince
James Passin CEO
 Chief Executive Officer 52 -
Kenneth Kovan FOU
 Founder - -
David Berd FOU
 Founder 79 20-09-29
Craig Loverock BRD
 Director/Board Member 53 22-09-07
Lachlan McLeod SEC
 Corporate Secretary 37 20-07-05

Members of the board

Members of the board TitleAgeSince
James Passin CEO
 Chief Executive Officer 52 -
Anthony Dutton BRD
 Director/Board Member 66 22-04-28
Craig Loverock BRD
 Director/Board Member 53 22-09-07
David Wang BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 210,813,161 196,885,828 ( 93.39 %) 0 93.39 %

Shareholders

NameEquities%Valuation
James Passin
11.15 %
16,177,333 11.15 % 905 931 $
Kenneth Kovan
5.067 %
7,352,862 5.067 % 411 760 $
David Berd
3.443 %
4,996,067 3.443 % 279 780 $
David Wang
1.029 %
1,492,575 1.029 % 83 584 $
Anthony Dutton
0.1723 %
250,000 0.1723 % 14 000 $
Craig Loverock
0.000000 %
0 0.000000 % - $

Company contact information

BioVaxys Technology Corp.

146 Thirtieth Street Suite 100

M8W 3C4, Etobicoke

+

http://www.biovaxys.com
address BioVaxys Technology Corp.(BIOV)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOVAXYS TECHNOLOGY CORP. Stock BioVaxys Technology Corp.
+70.00% 12.29M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.18% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.78% 97.42B
ARGENX SE Stock argenx SE
+1.43% 22.2B
BIONTECH SE Stock BioNTech SE
-17.99% 21.23B
GENMAB A/S Stock Genmab A/S
-10.90% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.28% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.56% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.74% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BIOV Stock
  4. Company BioVaxys Technology Corp.